Skip to main content
Home > BC Innovations > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Table 1: Ig therapies

    Cover Story: Invigorating IVIG Table 1. Ig therapies. At least nine blood-derived Ig products are marketed or approved and at least four next-generation products are in development. Source: BCIQ: BioCentury Online …

    Published on 10/9/2014
  • NAMPT neuroprotection

    Google-backed antiaging play Calico has filled its first pipeline program by in-licensing analogs of P7C3 after new research showed that the molecules block neurodegeneration by inhibiting NAMPT.

    Published on 10/2/2014
  • Interrupting Ebola

    Although different companies are pursuing antibodies, vaccines or siRNAs to fight Ebola, many researchers believe it is not a race between them but a combination of approaches that will win the day.

    Published on 9/25/2014
  • Table 1: Filovirus pipeline

    Cover Story: Interrupting Ebola Table 1. Filovirus pipeline. At least 16 products for filovirus are in development by public and private companies. Gray indicates therapies highlighted in the story. Source: BCIQ: …

    Published on 9/25/2014
  • Neutralizing HIV rebound

    Rockefeller University researchers have shown that broadly neutralizing antibodies against HIV envelope proteins can knock the virus out of its latent reservoirs, thus opening an inroad to fully eliminating HIV from …

    Published on 9/18/2014
  • Kinase convergence on eIF4F

    Researchers in France have shown that the eIF4F complex is a hub in which resistance pathways for BRAF and MEK converge and suggest that combining eIF4F inhibitors with marketed melanoma drugs could circumvent …

    Published on 9/11/2014
  • Box 1: eIF4A profiled

    Cover Story: Kinase convergence on eIF4F Box 1. eIF4A profiled. A team at the Memorial Sloan-Kettering Cancer Center has published data in Nature showing that inhibition of the RNA helicase eukaryotic translation …

    Published on 9/11/2014
  • Selectively splicing SMN2

    A three-way collaboration between PTC, Roche and the Spinal Muscular Atrophy Foundation has resulted in orally available, blood brain barrier-penetrant, selective small molecule modulators of SMN2 that are advancing in …

    Published on 9/4/2014
  • Figure 1: Modulating SMN2 splicing

    Cover Story: Selectively splicing SMN2 Figure 1. Modulating SMN2 splicing. Spinal muscular atrophy (SMA) is caused by insufficient expression of functional and stable survival of motor neuron (SMN) protein, leading …

    Published on 9/4/2014
  • Overcoming ibrutinib resistance

    The CDK4 inhibitor palbociclib might help overcome ibrutinib resistance in mantle cell lymphoma by restoring sensitivity to inhibitors of BTK or PI3K.

    Published on 8/28/2014
  • Figure 1: Blocking signaling to overcome Imbruvica resistance in MCL cells

    Cover Story: Overcoming ibrutinib resistance Figure 1. Blocking signaling to overcome Imbruvica resistance in MCL cells. [a] B cell receptor (BCR) stimulation by an extracellular antigen induces Bruton's tyrosine …

    Published on 8/28/2014
  • Table 1: CDK4 and CDK6 or BTK inhibitors in development for cancer

    Cover Story: Overcoming ibrutinib resistance Table 1. CDK4 and CDK6 or BTK inhibitors in development for cancer. At least five cyclin dependent kinase 4 (CDK4) and CDK6 inhibitors and five Bruton's tyrosine kinase (…

    Published on 8/28/2014
  • Fat chance for cancer cachexia

    With no drugs on the market and a pair of recent Phase III failures in cancer-associated cachexia, companies may consider targeting the cause of the wasting disease rather than its symptoms. Two independent academic …

    Published on 8/21/2014
  • Cancer-associated cachexia products in clinical development

    Cover Story: Fat chance for cancer cachexia Table 1. Cancer-associated cachexia products in clinical development. Although two compounds failed in Phase III trials for cancer cachexia, the landscape is still full of…

    Published on 8/21/2014
  • Navigating the new road in psychiatry

    The lack of predictive animal models for neuropsychiatric diseases is arguably the biggest single factor stifling early drug development in the field. To kick-start discovery for diseases such as autism, schizophrenia …

    Published on 8/14/2014
  • Box 1. Once more into the misfoldome

    Cover Story: Dyeing to diagnose preeclampsia Box 1. Once more into the misfoldome. In addition to identifying a method for diagnosing preeclampsia, the report in Science Translational Medicine suggests that the …

    Published on 8/7/2014
  • Dyeing to diagnose preeclampsia

    A Congo red-based urine test that could rapidly confirm a diagnosis of preeclampsia might avoid treatment delays. The method will be tested in an international trial next year and has been licensed by Yale spinout …

    Published on 8/7/2014
  • Fresh air for COPD

    An undisclosed company has picked up an integrin-targeting antibody from UCSF that could address the underlying pathology in COPD by improving airway remodeling via suppression of TGFB1.

    Published on 7/31/2014
  • Box 2: Considerations for compelling target and therapeutic validation

    Cover Story: It is an RNA world Box 2. Considerations for compelling target and therapeutic validation. · Empirical validation that the lncRNA target is expressed in the right place at the right time to impact the …

    Published on 7/24/2014
  • It is an RNA world

    RNA-based drugs have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent, turning RNA into the biotech industry's de facto third drug …

    Published on 7/24/2014
  • Table 1: 2014 first-quarter industry activity in RNA therapeutics

    Cover Story: It is an RNA world Table 1. 2014 first-quarter industry activity in RNA therapeutics. Deals involving Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) headline a barrage of activity totaling over $1 billion in…

    Published on 7/24/2014
  • Table 2: Accessible human tissues

    Cover Story: It is an RNA world Table 2. Accessible human tissues. Tissues that are accessible to single-stranded antisense and double-stranded RNAi therapeutics in human patients with exemplary therapeutics and …

    Published on 7/24/2014
  • Table 3: Orphan drug designations

    Cover Story: It is an RNA world Table 3. Orphan drug designations. Companies with RNA therapeutics programs receiving orphan drug designations from the FDA. Source:; BCIQ: BioCentury Online …

    Published on 7/24/2014
  • Table 4: Delivery platforms

    Cover Story: It is an RNA world Table 4. Delivery platforms. Platforms in clinical development to deliver RNA therapeutics in vivo. Platform Company Program Description Stage Encapsulation platforms Lipid …

    Published on 7/24/2014
  • Box 1: Attributes of the GalNAc-ASGR1 system

    Cover Story: It is an RNA world Box 1. Attributes of the GalNAc-ASGR1 system. · Ligand with nanomolar affinity for receptor · Tissue- or cell type-restricted expression of the receptor · High copy number of …

    Published on 7/24/2014

< Previous   1  2  3  4  5  6  Next >

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993